ATE182790T1 - Verwendung von aktin-bindenden verbindungen zur herstellung eines medikaments zur verminderung der viskosität von pathalogischen schleimartigen bestandteilen der atemwege - Google Patents
Verwendung von aktin-bindenden verbindungen zur herstellung eines medikaments zur verminderung der viskosität von pathalogischen schleimartigen bestandteilen der atemwegeInfo
- Publication number
- ATE182790T1 ATE182790T1 AT94914023T AT94914023T ATE182790T1 AT E182790 T1 ATE182790 T1 AT E182790T1 AT 94914023 T AT94914023 T AT 94914023T AT 94914023 T AT94914023 T AT 94914023T AT E182790 T1 ATE182790 T1 AT E182790T1
- Authority
- AT
- Austria
- Prior art keywords
- actin
- contents
- respiratory tract
- viscosity
- pathalogical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4716—Muscle proteins, e.g. myosin, actin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/53—Ligases (6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/042,247 US5464817A (en) | 1990-04-11 | 1993-04-02 | Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE182790T1 true ATE182790T1 (de) | 1999-08-15 |
Family
ID=21920852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT94914023T ATE182790T1 (de) | 1993-04-02 | 1994-04-04 | Verwendung von aktin-bindenden verbindungen zur herstellung eines medikaments zur verminderung der viskosität von pathalogischen schleimartigen bestandteilen der atemwege |
Country Status (17)
Country | Link |
---|---|
US (2) | US5464817A (de) |
EP (1) | EP0692970B1 (de) |
JP (2) | JPH08510998A (de) |
KR (1) | KR100308679B1 (de) |
CN (1) | CN1107521C (de) |
AT (1) | ATE182790T1 (de) |
AU (1) | AU695033B2 (de) |
BR (1) | BR9405856A (de) |
CA (1) | CA2159205A1 (de) |
DE (1) | DE69419907T2 (de) |
DK (1) | DK0692970T3 (de) |
ES (1) | ES2135576T3 (de) |
GB (1) | GB2293102B (de) |
GR (1) | GR3031753T3 (de) |
NO (1) | NO953862L (de) |
SG (1) | SG49574A1 (de) |
WO (1) | WO1994022465A1 (de) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5464817A (en) * | 1990-04-11 | 1995-11-07 | Brigham And Women's Hospital | Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I |
US5691160A (en) * | 1992-08-14 | 1997-11-25 | Biogen, Inc. | Effects of actin filaments of fibrin clot structure and lysis |
US5593964A (en) * | 1993-10-07 | 1997-01-14 | The George Washington University Medical Center | Method of treating septic shock by preventing actin polymerization |
US5578570A (en) * | 1993-10-07 | 1996-11-26 | The George Washington University Medical Center | Method of treating septic shock using thymosin β4 |
SK284191B6 (sk) * | 1995-02-24 | 2004-10-05 | Genentech, Inc. | Aktín-rezistentný variant humánnej DNázy I |
JPH11505408A (ja) * | 1995-02-24 | 1999-05-21 | ジェネンテック インコーポレーテッド | ヒトdnアーゼ変異体 |
US6348343B2 (en) | 1995-02-24 | 2002-02-19 | Genentech, Inc. | Human DNase I variants |
PT854927E (pt) * | 1995-10-10 | 2008-09-08 | Genentech Inc | Variantes da adnase i humana |
US6391607B1 (en) | 1996-06-14 | 2002-05-21 | Genentech, Inc. | Human DNase I hyperactive variants |
CA2274002A1 (en) | 1996-12-04 | 1998-06-11 | The Victoria University Of Manchester | Wound healing and treatment of fibrosis |
EP1249244A1 (de) * | 2001-04-13 | 2002-10-16 | Universiteit Gent | Therapeutische Zusammensetzungen zur Behandlung einer g-actin / f-actin-gleichgewicht vermittelten Erkrankung, z.b. einer respiratorischen Erkrankung |
CA2439471A1 (en) * | 2001-12-28 | 2003-07-17 | Daiichi Suntory Pharma Co., Ltd. | Promoters of the growth and/or differentiation of hematopoietic stem cells and/or hematopoietic progenitors |
US8431123B2 (en) * | 2003-07-14 | 2013-04-30 | Cls Therapeutics Limited | Method for treating systemic bacterial, fungal and protozoan infection |
US8388951B2 (en) | 2003-07-14 | 2013-03-05 | Cls Therapeutics Limited | Method for treating systemic DNA mutation disease |
WO2005004904A1 (fr) * | 2003-07-14 | 2005-01-20 | Dmitry Dmitrievich Genkin | Methode de traitement de maladies s'accompagnant d'alterations de la composition qualitative et/ou quantitative de l'adn extracellulaire du sang (variantes) |
US8710012B2 (en) * | 2003-07-14 | 2014-04-29 | Cls Therapeutics Limited | Method for treating oncological diseases |
GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
US9408891B2 (en) * | 2003-11-12 | 2016-08-09 | The Trustees Of The University Of Pennsylvania | Methods of using gelsolin to treat or prevent bacterial sepsis |
PL1694342T3 (pl) * | 2003-11-12 | 2021-07-05 | Trustees Of The University Of Pennsylvania | Sposoby zastosowania gelsoliny do leczenia lub zapobiegania posocznicy bakteryjnej |
US8518457B2 (en) * | 2004-05-11 | 2013-08-27 | Pulmonox Technologies Corporation | Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant |
WO2005112970A2 (en) * | 2004-05-12 | 2005-12-01 | The Brigham And Women's Hospital, Inc. | Use of gelsolin to treat infections |
CA2578478A1 (en) | 2004-08-06 | 2006-02-16 | National Jewish Medical And Research Center | Product and process for inhibition of biofilm development |
EP1880733A4 (de) * | 2005-04-25 | 2009-08-12 | Genkin Dmitry Dmitrievich | Verfahren zur verlängerung der lebensdauer eines menschen und von tieren |
PL3279663T3 (pl) | 2006-03-15 | 2022-01-10 | The Brigham And Women's Hospital, Inc. | Zastosowanie gelsoliny do diagnozowania i leczenia chorób zapalnych |
US8440622B2 (en) * | 2006-03-15 | 2013-05-14 | The Brigham And Women's Hospital, Inc. | Use of gelsolin to treat multiple sclerosis and to diagnose neurologic disease (stossel) |
JP5372769B2 (ja) * | 2006-11-28 | 2013-12-18 | シーエルエス セラピューティック リミティド | 組織の細胞外間隙においてデオキシリボ核酸の量が増量することに関連するヒトの病気の治療方法及び該方法を実施するための医薬製剤 |
US8753662B2 (en) * | 2007-02-15 | 2014-06-17 | National Jewish Health | Methods and compositions for the disruption of biofilms |
DK2250280T3 (en) * | 2008-01-25 | 2015-03-09 | Gen Hospital Corp | THERAPEUTIC USES OF gelsolin in renal failure |
US20150010527A1 (en) | 2012-02-01 | 2015-01-08 | Protalix Ltd. | Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy |
US10617743B2 (en) | 2014-06-19 | 2020-04-14 | Cls Therapeutics Limited | Method to improve safety and efficacy of anti-cancer therapy |
RU2726131C2 (ru) | 2015-05-22 | 2020-07-09 | Дмитрий Дмитриевич Генкин | Внеклеточная днк в качестве терапевтической мишени при нейродегенерации |
AU2019209770A1 (en) | 2018-01-16 | 2020-09-03 | Cls Therapeutics Limited | Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5464817A (en) * | 1990-04-11 | 1995-11-07 | Brigham And Women's Hospital | Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I |
ES2124702T3 (es) * | 1990-04-11 | 1999-02-16 | Brigham & Womens Hospital | Usos terapeuticos de compuestos que se unen a actina. |
US5691160A (en) * | 1992-08-14 | 1997-11-25 | Biogen, Inc. | Effects of actin filaments of fibrin clot structure and lysis |
-
1993
- 1993-04-02 US US08/042,247 patent/US5464817A/en not_active Expired - Lifetime
-
1994
- 1994-04-04 GB GB9520020A patent/GB2293102B/en not_active Expired - Fee Related
- 1994-04-04 DK DK94914023T patent/DK0692970T3/da active
- 1994-04-04 JP JP6522448A patent/JPH08510998A/ja active Pending
- 1994-04-04 ES ES94914023T patent/ES2135576T3/es not_active Expired - Lifetime
- 1994-04-04 EP EP94914023A patent/EP0692970B1/de not_active Expired - Lifetime
- 1994-04-04 AT AT94914023T patent/ATE182790T1/de not_active IP Right Cessation
- 1994-04-04 AU AU66250/94A patent/AU695033B2/en not_active Ceased
- 1994-04-04 SG SG1995001962A patent/SG49574A1/en unknown
- 1994-04-04 CN CN94191951A patent/CN1107521C/zh not_active Expired - Fee Related
- 1994-04-04 KR KR1019950704203A patent/KR100308679B1/ko not_active IP Right Cessation
- 1994-04-04 WO PCT/US1994/003667 patent/WO1994022465A1/en active IP Right Grant
- 1994-04-04 CA CA002159205A patent/CA2159205A1/en not_active Abandoned
- 1994-04-04 BR BR9405856A patent/BR9405856A/pt not_active Application Discontinuation
- 1994-04-04 DE DE69419907T patent/DE69419907T2/de not_active Expired - Fee Related
-
1995
- 1995-06-02 US US08/458,351 patent/US5656589A/en not_active Expired - Fee Related
- 1995-09-29 NO NO953862A patent/NO953862L/no not_active Application Discontinuation
-
1999
- 1999-11-04 GR GR990402778T patent/GR3031753T3/el unknown
-
2001
- 2001-04-03 JP JP2001105286A patent/JP2001302537A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DK0692970T3 (da) | 1999-12-06 |
JP2001302537A (ja) | 2001-10-31 |
AU6625094A (en) | 1994-10-24 |
CN1107521C (zh) | 2003-05-07 |
GB2293102A (en) | 1996-03-20 |
BR9405856A (pt) | 1996-03-05 |
GB9520020D0 (en) | 1995-12-06 |
EP0692970B1 (de) | 1999-08-04 |
EP0692970A1 (de) | 1996-01-24 |
GR3031753T3 (en) | 2000-02-29 |
ES2135576T3 (es) | 1999-11-01 |
WO1994022465A1 (en) | 1994-10-13 |
CA2159205A1 (en) | 1994-10-13 |
DE69419907T2 (de) | 1999-12-09 |
JPH08510998A (ja) | 1996-11-19 |
GB2293102B (en) | 1996-10-09 |
NO953862D0 (no) | 1995-09-29 |
AU695033B2 (en) | 1998-08-06 |
SG49574A1 (en) | 1998-06-15 |
CN1122108A (zh) | 1996-05-08 |
US5464817A (en) | 1995-11-07 |
NO953862L (no) | 1995-09-29 |
KR100308679B1 (ko) | 2001-11-30 |
DE69419907D1 (de) | 1999-09-09 |
US5656589A (en) | 1997-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE182790T1 (de) | Verwendung von aktin-bindenden verbindungen zur herstellung eines medikaments zur verminderung der viskosität von pathalogischen schleimartigen bestandteilen der atemwege | |
DE69738522D1 (de) | Ein verfahren zur inhibierung immunglobulininduzierter toxizität aufgrund von der verwendung von immunoglobinen in therapie und in vivo diagnostik | |
DE69130289T2 (de) | Therapeutische verwendung von actin-bindenden verbindungen | |
EA200000748A1 (ru) | Способ введения мономерных аналогов инсулина | |
BR9915940A (pt) | Métodos e composições para restaurar a estabilidade conformacional de uma proteìna da famìlia p53 | |
DE69331045T2 (de) | Verwendung von igf-1 | |
KR920700667A (ko) | 세포간 점착분자 및 그의 결합리간드의 천식치료에의 이용 | |
DE68907679D1 (de) | Sauerwiderstehender fibroblast-wachstumsfaktor, zubereitung zur behandlung von magen-darmweg-geschwuerkrankheiten. | |
Samper Agrelo et al. | Secretome analysis of mesenchymal stem cell factors fostering oligodendroglial differentiation of neural stem cells in vivo | |
GR1000172B (el) | Βελτιωσεις εις η εν σχεσει προς τις σωματοστατινες. | |
ATE104855T1 (de) | Verwendung von inositoltrisphosphat zur herstellung eines arzneimittels gegen knochenerkrakungen. | |
EP1281763A3 (de) | Early growth response-1 (EGR-1) transkriptions-faktor | |
ATE191568T1 (de) | Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine | |
DE69433682D1 (de) | Wässrige proteinzusammensetzung, enthaltende glykoproteine, verfahren zur herstellung und verwendungen | |
Nelson | Ethanol protection against the catalase-depressing effect of 3-amino-1, 2, 4-triazole | |
DE69728654D1 (de) | Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus | |
BR9510323A (pt) | Variante de dnase i humana ácido nucleico isolado método para tratamento de um paciente tendo uma desordem ou doença pulmonar e composição farmacêutica | |
BR0002726A (pt) | Uso e preparação contendo derivados de hemoglobina para a determinação do volume do plasma e/ou do sangue | |
KR950003312A (ko) | 연골세포 단백질 | |
Brancaccio et al. | Purification and partial characterization of a new 85 KDa amyloidosis-related protein in chronic hemodialysis | |
Sakai et al. | Studies on the Gastric Juice Protein (I): On the" Peptide Portion" of the Gastric Juice by the Paper-Electrophoresis-Polarogram | |
RIDDLE | The Blood Sugar During Remission in Pernicious Anemia | |
ATE85893T1 (de) | Verwendung von somatostatin zur herstellung eines arzneimittels fuer die behandlung von rheumatoider arthritis. | |
Butler | Free radicals in molecular biology aging and disease (Aging, Volume 27) | |
WO1994015962A3 (en) | Derivatized calcitonins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REN | Ceased due to non-payment of the annual fee |